Globe Life (GL, Life insurers) Stock Valuation & Fair Value Favorable on our tests
Globe Life (GL, Life insurers) trades at a current P/E of 10.6, about 12% below its historical normal valuation, with a forward growth estimate of 6.7% and a PEG of 1.58. Analysts' one-year estimates have been hit 82% of the time. Priced at its historical normal P/E of 12.1 on the same blended earnings, the 2026-10-09 close of $164.17 corresponds to about $187 a share. This is a valuation reference, not a price target.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation and forecast return, and for the top ratings, credit rating, growth and analyst accuracy.
- Price $165.12 at the 2026-10-12 close, 1.5% below the 20-day average ($167.64) and 4.4% below the 50-day ($172.65).
- RSI (14) at 40.1.
- 52-week range $129.31 to $185.65: the price is 11.1% below the high and 27.7% above the low.
The Street vs SeerForecast
Wall Street's mean price target for GL is $192.91 across 11 analysts, 16.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: favorable on our tests. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating moved from mixed on our tests (2026-06-03) to favorable on our tests (2026-10-12). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 39 weeks
Frequently asked questions
Is Globe Life stock overvalued?
At a current P/E of 10.6 versus its historical normal P/E of 12.1, Globe Life trades about 12% below its typical valuation, with a PEG of 1.58 on 6.7% forward growth. tickerseer currently rates it favorable on our tests.
What is Globe Life's fair value and PEG?
Globe Life trades at a current P/E of 10.6 against a historical normal P/E of 12.1, a PEG of 1.58, and a forward growth estimate of 6.7%. Priced at its historical normal P/E of 12.1 on the same blended earnings, the 2026-10-09 close of $164.17 corresponds to about $187 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Globe Life changed?
tickerseer's rating moved from mixed on our tests (2026-06-03) to favorable on our tests (2026-10-12). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Globe Life?
The mean Wall Street price target for Globe Life is $192.91 across 11 analysts, 16.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Life insurers. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.